Blocking  ||| S:0 E:9 ||| VBG
initial  ||| S:9 E:17 ||| JJ
infiltration  ||| S:17 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
pioneer  ||| S:33 E:41 ||| CD
CD8 ||| S:41 E:44 ||| CD
( ||| S:44 E:45 ||| -LRB-
+ ||| S:45 E:46 ||| NNP
)  ||| S:46 E:48 ||| -RRB-
T-cells  ||| S:48 E:56 ||| JJ
into  ||| S:56 E:61 ||| IN
the  ||| S:61 E:65 ||| DT
CNS  ||| S:65 E:69 ||| NNP
via  ||| S:69 E:73 ||| IN
inhibition  ||| S:73 E:84 ||| NN
of  ||| S:84 E:87 ||| IN
SHP-2  ||| S:87 E:93 ||| FW
ameliorates  ||| S:93 E:105 ||| FW
experimental  ||| S:105 E:118 ||| FW
autoimmune  ||| S:118 E:129 ||| FW
encephalomyelitis  ||| S:129 E:147 ||| FW
in  ||| S:147 E:150 ||| IN
mice  ||| S:150 E:155 ||| NNS
In  ||| S:155 E:158 ||| IN
contrast  ||| S:158 E:167 ||| NN
to  ||| S:167 E:170 ||| TO
T-cell  ||| S:170 E:177 ||| JJ
priming  ||| S:177 E:185 ||| NN
in  ||| S:185 E:188 ||| IN
the  ||| S:188 E:192 ||| DT
periphery ||| S:192 E:201 ||| NN
,  ||| S:201 E:203 ||| ,
therapeutic  ||| S:203 E:215 ||| JJ
strategies  ||| S:215 E:226 ||| NNS
targeting  ||| S:226 E:236 ||| VBG
the  ||| S:236 E:240 ||| DT
initiation  ||| S:240 E:251 ||| JJ
step  ||| S:251 E:256 ||| NN
of  ||| S:256 E:259 ||| IN
T-cell  ||| S:259 E:266 ||| JJ
trafficking  ||| S:266 E:278 ||| NN
into  ||| S:278 E:283 ||| IN
the  ||| S:283 E:287 ||| DT
CNS  ||| S:287 E:291 ||| NNP
have  ||| S:291 E:296 ||| VBP
not  ||| S:296 E:300 ||| RB
been  ||| S:300 E:305 ||| VBN
extensively  ||| S:305 E:317 ||| RB
investigated ||| S:317 E:329 ||| VBN
.  ||| S:329 E:331 ||| .
In  ||| S:331 E:334 ||| IN
this  ||| S:334 E:339 ||| DT
study ||| S:339 E:344 ||| NN
,  ||| S:344 E:346 ||| ,
we  ||| S:346 E:349 ||| PRP
examined  ||| S:349 E:358 ||| VBD
the  ||| S:358 E:362 ||| DT
effect  ||| S:362 E:369 ||| NN
of  ||| S:369 E:372 ||| IN
NSC-87877 ||| S:372 E:381 ||| NNP
,  ||| S:381 E:383 ||| ,
a  ||| S:383 E:385 ||| DT
potent  ||| S:385 E:392 ||| FW
Src  ||| S:392 E:396 ||| FW
homology  ||| S:396 E:405 ||| FW
2-containing  ||| S:405 E:418 ||| FW
protein  ||| S:418 E:426 ||| FW
tyrosine  ||| S:426 E:435 ||| FW
phosphatase  ||| S:435 E:447 ||| JJ
2  ||| S:447 E:449 ||| CD
( ||| S:449 E:450 ||| -LRB-
SHP-2 ||| S:450 E:455 ||| NNP
)  ||| S:455 E:457 ||| -RRB-
inhibitor ||| S:457 E:466 ||| NN
,  ||| S:466 E:468 ||| ,
on  ||| S:468 E:471 ||| IN
experimental  ||| S:471 E:484 ||| JJ
autoimmune  ||| S:484 E:495 ||| JJ
encephalomyelitis  ||| S:495 E:513 ||| NNS
( ||| S:513 E:514 ||| -LRB-
EAE ||| S:514 E:517 ||| NNP
)  ||| S:517 E:519 ||| -RRB-
and  ||| S:519 E:523 ||| CC
elucidated  ||| S:523 E:534 ||| VB
its  ||| S:534 E:538 ||| PRP$
unique  ||| S:538 E:545 ||| JJ
mechanism  ||| S:545 E:555 ||| NN
of  ||| S:555 E:558 ||| IN
action ||| S:558 E:564 ||| NN
.  ||| S:564 E:566 ||| .
C57BL ||| S:566 E:571 ||| CD
/ ||| S:571 E:572 ||| CD
6  ||| S:572 E:574 ||| CD
mice  ||| S:574 E:579 ||| NNS
were  ||| S:579 E:584 ||| VBD
immunized  ||| S:584 E:594 ||| VBN
with  ||| S:594 E:599 ||| IN
myelin  ||| S:599 E:606 ||| JJ
oligodendrocyte  ||| S:606 E:622 ||| JJ
glycoprotein35-55  ||| S:622 E:640 ||| NN
and  ||| S:640 E:644 ||| CC
monitored  ||| S:644 E:654 ||| VBN
for  ||| S:654 E:658 ||| IN
clinical  ||| S:658 E:667 ||| JJ
severity  ||| S:667 E:676 ||| NN
of  ||| S:676 E:679 ||| IN
disease  ||| S:679 E:687 ||| NN
and  ||| S:687 E:691 ||| CC
histopathological  ||| S:691 E:709 ||| JJ
features  ||| S:709 E:718 ||| NNS
in  ||| S:718 E:721 ||| IN
the  ||| S:721 E:725 ||| DT
CNS ||| S:725 E:728 ||| NNP
.  ||| S:728 E:730 ||| .
Levels  ||| S:730 E:737 ||| NNS
of  ||| S:737 E:740 ||| IN
cytokines  ||| S:740 E:750 ||| NN
in  ||| S:750 E:753 ||| IN
serum  ||| S:753 E:759 ||| NN
were  ||| S:759 E:764 ||| VBD
measured  ||| S:764 E:773 ||| VBN
by  ||| S:773 E:776 ||| IN
elisa ||| S:776 E:781 ||| NN
.  ||| S:781 E:783 ||| .
Effects  ||| S:783 E:791 ||| NNS
of  ||| S:791 E:794 ||| IN
NSC-87877  ||| S:794 E:804 ||| CD
on  ||| S:804 E:807 ||| IN
expressions  ||| S:807 E:819 ||| NNS
of  ||| S:819 E:822 ||| IN
chemokines  ||| S:822 E:833 ||| NN
and  ||| S:833 E:837 ||| CC
cytokines  ||| S:837 E:847 ||| NN
in  ||| S:847 E:850 ||| IN
the  ||| S:850 E:854 ||| DT
CNS  ||| S:854 E:858 ||| NNP
were  ||| S:858 E:863 ||| VBD
determined  ||| S:863 E:874 ||| VBN
by  ||| S:874 E:877 ||| IN
quantitative  ||| S:877 E:890 ||| JJ
PCR ||| S:890 E:893 ||| NNP
.  ||| S:893 E:895 ||| .
NSC-87877-treated  ||| S:895 E:913 ||| NNP
mice  ||| S:913 E:918 ||| NNS
developed  ||| S:918 E:928 ||| VBD
conventional  ||| S:928 E:941 ||| JJ
TH  ||| S:941 E:944 ||| NNP
1  ||| S:944 E:946 ||| CD
and  ||| S:946 E:950 ||| CC
TH  ||| S:950 E:953 ||| NNP
17  ||| S:953 E:956 ||| CD
responses ||| S:956 E:965 ||| NNS
,  ||| S:965 E:967 ||| ,
but  ||| S:967 E:971 ||| CC
were  ||| S:971 E:976 ||| VBD
highly  ||| S:976 E:983 ||| RB
resistant  ||| S:983 E:993 ||| JJ
to  ||| S:993 E:996 ||| TO
the  ||| S:996 E:1000 ||| DT
induction  ||| S:1000 E:1010 ||| NN
of  ||| S:1010 E:1013 ||| IN
EAE ||| S:1013 E:1016 ||| NNP
.  ||| S:1016 E:1018 ||| .
NSC-87877  ||| S:1018 E:1028 ||| NNP
decreased  ||| S:1028 E:1038 ||| VBD
the  ||| S:1038 E:1042 ||| DT
accumulation  ||| S:1042 E:1055 ||| NN
of  ||| S:1055 E:1058 ||| IN
lymphocytes  ||| S:1058 E:1070 ||| NN
in  ||| S:1070 E:1073 ||| IN
the  ||| S:1073 E:1077 ||| DT
CNS  ||| S:1077 E:1081 ||| NNP
and  ||| S:1081 E:1085 ||| CC
increased  ||| S:1085 E:1095 ||| VBD
the  ||| S:1095 E:1099 ||| DT
functional  ||| S:1099 E:1110 ||| JJ
expression  ||| S:1110 E:1121 ||| NN
of  ||| S:1121 E:1124 ||| IN
chemokine  ||| S:1124 E:1134 ||| JJ
receptor  ||| S:1134 E:1143 ||| NN
CXCR7  ||| S:1143 E:1149 ||| NN
on  ||| S:1149 E:1152 ||| IN
CD8 ||| S:1152 E:1155 ||| NNP
( ||| S:1155 E:1156 ||| -LRB-
+ ||| S:1156 E:1157 ||| NNP
)  ||| S:1157 E:1159 ||| -RRB-
T-cells ||| S:1159 E:1166 ||| JJ
.  ||| S:1166 E:1168 ||| .
Adoptive  ||| S:1168 E:1177 ||| JJ
transfer  ||| S:1177 E:1186 ||| NN
of  ||| S:1186 E:1189 ||| IN
T-cells  ||| S:1189 E:1197 ||| JJ
from  ||| S:1197 E:1202 ||| IN
2D2-transgenic  ||| S:1202 E:1217 ||| CD
mice  ||| S:1217 E:1222 ||| NNS
restored  ||| S:1222 E:1231 ||| VBD
EAE  ||| S:1231 E:1235 ||| NNP
susceptibility  ||| S:1235 E:1250 ||| NN
in  ||| S:1250 E:1253 ||| IN
NSC-87877-treated  ||| S:1253 E:1271 ||| CD
mice ||| S:1271 E:1275 ||| NNS
,  ||| S:1275 E:1277 ||| ,
indicating  ||| S:1277 E:1288 ||| VBG
that  ||| S:1288 E:1293 ||| IN
NSC-87877  ||| S:1293 E:1303 ||| NNP
only  ||| S:1303 E:1308 ||| RB
targets  ||| S:1308 E:1316 ||| VBZ
the  ||| S:1316 E:1320 ||| DT
initial  ||| S:1320 E:1328 ||| JJ
migration  ||| S:1328 E:1338 ||| NN
of  ||| S:1338 E:1341 ||| IN
pioneer  ||| S:1341 E:1349 ||| JJ
T-cells ||| S:1349 E:1356 ||| NN
.  ||| S:1356 E:1358 ||| .
Furthermore ||| S:1358 E:1369 ||| RB
,  ||| S:1369 E:1371 ||| ,
T-cell-conditioned  ||| S:1371 E:1390 ||| JJ
SHP-2-deficient  ||| S:1390 E:1406 ||| CD
mice  ||| S:1406 E:1411 ||| NNS
treated  ||| S:1411 E:1419 ||| VBN
with  ||| S:1419 E:1424 ||| IN
NSC-87877  ||| S:1424 E:1434 ||| NNP
were  ||| S:1434 E:1439 ||| VBD
no  ||| S:1439 E:1442 ||| DT
longer  ||| S:1442 E:1449 ||| RBR
resistant  ||| S:1449 E:1459 ||| JJ
to  ||| S:1459 E:1462 ||| TO
EAE ||| S:1462 E:1465 ||| NNP
,  ||| S:1465 E:1467 ||| ,
suggesting  ||| S:1467 E:1478 ||| VBG
that  ||| S:1478 E:1483 ||| DT
inhibition  ||| S:1483 E:1494 ||| NN
of  ||| S:1494 E:1497 ||| IN
SHP-2  ||| S:1497 E:1503 ||| NNP
contributes  ||| S:1503 E:1515 ||| VBZ
to  ||| S:1515 E:1518 ||| TO
the  ||| S:1518 E:1522 ||| DT
amelioration  ||| S:1522 E:1535 ||| NN
of  ||| S:1535 E:1538 ||| IN
EAE  ||| S:1538 E:1542 ||| NNP
by  ||| S:1542 E:1545 ||| IN
NSC-87877 ||| S:1545 E:1554 ||| CD
.  ||| S:1554 E:1556 ||| .
NSC-87877  ||| S:1556 E:1566 ||| NNP
almost  ||| S:1566 E:1573 ||| RB
completely  ||| S:1573 E:1584 ||| RB
abolished  ||| S:1584 E:1594 ||| VBN
the  ||| S:1594 E:1598 ||| DT
development  ||| S:1598 E:1610 ||| NN
of  ||| S:1610 E:1613 ||| IN
EAE  ||| S:1613 E:1617 ||| NNP
by  ||| S:1617 E:1620 ||| IN
blocking  ||| S:1620 E:1629 ||| VBG
the  ||| S:1629 E:1633 ||| DT
initial  ||| S:1633 E:1641 ||| JJ
infiltration  ||| S:1641 E:1654 ||| NN
of  ||| S:1654 E:1657 ||| IN
pioneer  ||| S:1657 E:1665 ||| CD
CD8 ||| S:1665 E:1668 ||| CD
( ||| S:1668 E:1669 ||| -LRB-
+ ||| S:1669 E:1670 ||| NNP
)  ||| S:1670 E:1672 ||| -RRB-
T-cells  ||| S:1672 E:1680 ||| JJ
into  ||| S:1680 E:1685 ||| IN
the  ||| S:1685 E:1689 ||| DT
uninflamed  ||| S:1689 E:1700 ||| JJ
CNS ||| S:1700 E:1703 ||| NNP
.  ||| S:1703 E:1705 ||| .
These  ||| S:1705 E:1711 ||| DT
results  ||| S:1711 E:1719 ||| NNS
reveal  ||| S:1719 E:1726 ||| VBP
a  ||| S:1726 E:1728 ||| DT
critical  ||| S:1728 E:1737 ||| JJ
role  ||| S:1737 E:1742 ||| NN
for  ||| S:1742 E:1746 ||| IN
SHP-2  ||| S:1746 E:1752 ||| CD
in  ||| S:1752 E:1755 ||| IN
regulating  ||| S:1755 E:1766 ||| VBG
EAE  ||| S:1766 E:1770 ||| NNP
pathogenesis  ||| S:1770 E:1783 ||| NN
and  ||| S:1783 E:1787 ||| CC
indicate  ||| S:1787 E:1796 ||| VB
that  ||| S:1796 E:1801 ||| IN
NSC-87877  ||| S:1801 E:1811 ||| NNP
is  ||| S:1811 E:1814 ||| VBZ
a  ||| S:1814 E:1816 ||| DT
potential  ||| S:1816 E:1826 ||| JJ
candidate  ||| S:1826 E:1836 ||| NN
for  ||| S:1836 E:1840 ||| IN
the  ||| S:1840 E:1844 ||| DT
treatment  ||| S:1844 E:1854 ||| NN
of  ||| S:1854 E:1857 ||| IN
relapsing-remitting  ||| S:1857 E:1877 ||| JJ
multiple  ||| S:1877 E:1886 ||| JJ
sclerosis ||| S:1886 E:1895 ||| NN
.  ||| S:1895 E:1897 ||| .
